In MLL-AF9 leukemia models overexpressing BCL-2 and MCL-1 it was provided evidence that the combination of BCL-2 and MCL-1 inhibitors resulted in a synergistic anti-leukemic effect, when used alone or in combination with standard anti-leukemic drugs [119]. The gene discussed is BCL2; the disease is leukemia.